Hilton wrote "In my experience (as a clinician-scientist) most companies will release the top line results of a major clinical trial at a meeting along with the simultaneous publication of the results in a journal."

Incorrect. Almost all cardiovascular outcomes trials first release top-line data first via a news release and then present & publish full detailed data later. Pomponius Capital gave you the REDUCE-IT example for which top-line data was news released September 24, 2018 and then full data presented and published at AHA in November 2018. Numerous other examples of top-line first are compiled in this post (slightly outdated). One recent and rare exception to this trend is the ODYSSEY trial for Praluent/alirocumab PCSK9 inhibitor in which there was no data reveal prior to full data set being revealed and presented at March 10, 2018 ACC meeting. This is rare and not the norm. 

Hilton's example is a poor one. Amgen first released top-line data for Fourier in February 2017 and full data at ACC in March 2017. Hilton's example link was a subsequent sub-study if Fourier presented in September 2017. 

Perhaps full BETonMACE data in Paris, Hilton, at ESC 2019 with top-line coming just before?

BearDownAZ